Dynavax Technologies - DVAX Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DVAX shares.
View DVAX analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month target prices for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $28.00. On average, they expect the company's share price to reach $23.67 in the next year. This suggests a possible upside of 86.1% from the stock's current price.
View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts.

Dynavax Technologies' stock was trading at $14.07 at the beginning of 2022. Since then, DVAX stock has decreased by 9.6% and is now trading at $12.72.
View the best growth stocks for 2022 here.

Dynavax Technologies saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 15,730,000 shares, an increase of 9.2% from the October 31st total of 14,400,000 shares. Based on an average daily volume of 1,850,000 shares, the short-interest ratio is presently 8.5 days.
View Dynavax Technologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our DVAX earnings forecast.

Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analysts' expectations of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 90.54% and a net margin of 44.35%. During the same period in the previous year, the firm posted ($0.15) EPS.

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.50%), Federated Hermes Inc. (9.89%), State Street Corp (8.05%), Vanguard Group Inc. (6.40%), Chicago Capital LLC (4.59%) and Bain Capital Life Sciences Investors LLC (4.24%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends.

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DVAX stock can currently be purchased for approximately $12.72.

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.62 billion and generates $439.44 million in revenue each year. The biopharmaceutical company earns $76.71 million in net income (profit) each year or $2.07 on an earnings per share basis.

The company employs 311 workers across the globe.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327.